Exelixis | EXEL

Stock Price
19.20
Daily Change
-0.78%
Yearly
5.84%
Q2 Forecast
18.63
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 4,532.00 51.00 1.14% 24.78%
Eisai 10,590.00 285.00 2.77% 96.29%
Acadia Pharmaceuticals 24.72 -0.37 -1.47% 44.65%
Agios Pharmaceuticals 25.87 -0.73 -2.74% 39.84%
Akebia Therapeutics 1.26 0.01 0.80% 209.13%
Amgen 218.76 -2.00 -0.91% -8.85%
AstraZeneca 11,712.00 -38.00 -0.32% 18.89%
Bayer 51.15 -0.80 -1.54% -19.52%
Bluebird Bio 3.65 -0.11 -2.93% -14.52%
BioMarin Pharmaceutical 91.37 -0.89 -0.96% 21.70%
Bristol-Myers Squibb 64.80 -0.51 -0.78% -13.70%
Cytokinetics 37.03 -1.03 -2.71% -6.25%
Esperion Therapeutics 1.30 -0.05 -3.70% -76.23%
Exelixis 19.20 -0.15 -0.78% 5.84%
Genmab 2,676.00 -12.00 -0.45% 29.53%
Glaxosmithkline 34.76 0.04 0.12% -20.64%
Immunogen 17.16 1.41 8.95% 406.19%
Incyte Corp 61.04 -0.47 -0.76% -13.30%
Ionis Pharmaceuticals 40.65 -1.00 -2.40% 16.94%
Eli Lilly 446.04 0.38 0.09% 50.18%
MacroGenics 5.56 0.36 6.92% 98.57%
Merck & Co 110.71 0.39 0.35% 26.99%
Moderna 123.26 -1.68 -1.34% -3.04%
Mirati Therapeutics 37.98 -0.73 -1.89% -35.70%
Neurocrine Biosciences 93.39 -0.64 -0.68% -0.98%
Nektar Therapeutics 0.59 -0.02 -2.90% -82.38%
Novartis 90.17 -0.20 -0.22% 7.45%
Puma Biotechnology 3.38 -0.13 -3.70% 30.50%
Pfizer 38.97 -0.12 -0.31% -22.01%
Ultragenyx Pharmaceutical 51.38 -0.20 -0.39% 3.01%
Seattle Genetics 196.60 1.88 0.97% 41.03%
Sanofi 51.24 -0.30 -0.58% 0.65%
Xencor 26.87 -0.38 -1.39% 30.88%

Indexes Price Day Year
USND 13259 20.62 0.16% 16.92%
US2000 1866 -15.07 -0.80% 3.63%
US400 2542 -14.91 -0.58% 5.80%

Exelixis

Exelixis traded at $19.20 this Friday June 9th, decreasing $0.15 or 0.78 percent since the previous trading session. Looking back, over the last four weeks, Exelixis lost 0.93 percent. Over the last 12 months, its price rose by 5.84 percent. Looking ahead, we forecast Exelixis to be priced at 18.63 by the end of this quarter and at 17.06 in one year, according to Trading Economics global macro models projections and analysts expectations.

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.